Polymyositis

Populations and Risk Factors

Adults aged 30–60 years (peak incidence); rare in children (juvenile dermatomyositis is more common in pediatric populations)
Women affected approximately 2:1 over men
Higher prevalence in African American populations
Genetic susceptibility: HLA-DRB1 alleles associated; specific alleles vary by ethnicity
May overlap with other autoimmune conditions: lupus, scleroderma, Sjogren syndrome, rheumatoid arthritis (overlap myositis)
Associated with increased risk of malignancy — particularly in adults over 40 at diagnosis; malignancy screening is standard of care at diagnosis and during follow-up (most commonly ovarian, lung, breast, GI, and lymphoma)
Associated with interstitial lung disease (ILD) — anti-Jo-1 antibody positive patients have the highest risk (~50% develop ILD)
Environmental triggers hypothesized: viral infections (Coxsackievirus, HIV), certain medications (statins, penicillamine, interferon-alpha)

Causes and Pathophysiology

Autoimmune Muscle Destruction — The Core Mechanism

Cell-mediated attack: In polymyositis, CD8+ cytotoxic T-lymphocytes recognize an unknown antigen on the surface of skeletal muscle fibers (via MHC class I presentation, which is abnormally upregulated on muscle fibers in polymyositis). The T-cells directly invade individual muscle fibers, forming an endomysial infiltrate — inflammation within the muscle fascicles surrounding and destroying individual fibers. This is the histological hallmark that distinguishes polymyositis from dermatomyositis.
Why endomysial (not perimysial): The distinction matters. In polymyositis, the T-cells attack the muscle fibers directly → endomysial inflammation (within the fascicle, around individual fibers). In dermatomyositis, the immune attack targets the intramuscular microvasculature → perimysial inflammation (around the fascicles, in the connective tissue between bundles) with perifascicular atrophy. This pathological difference explains why dermatomyositis produces skin findings (vascular inflammation affects skin vasculature) and polymyositis does not.
Muscle fiber necrosis and CK release: Destroyed muscle fibers release their intracellular contents into the bloodstream — creatine kinase (CK), aldolase, lactate dehydrogenase (LDH), and myoglobin. CK is the most clinically useful marker: levels may rise to 5–50 times normal during active disease. CK levels correlate with disease activity and are used to monitor treatment response — falling CK indicates effective immunosuppression.

Why Proximal Muscles Are Targeted

Proximal predominance: Polymyositis characteristically affects proximal muscles (shoulder girdle, hip girdle, neck flexors) more than distal muscles. The exact mechanism for this selectivity is not fully understood but is hypothesized to relate to: (1) higher metabolic demand and blood flow in proximal muscles making them more accessible to circulating immune cells; (2) greater density of MHC class I expression in proximal muscle fibers; (3) the larger fiber cross-sectional area of proximal muscles presenting a greater target surface.
Functional consequence: Proximal weakness produces characteristic disability: the patient cannot rise from a chair without using their arms, cannot climb stairs, cannot lift objects overhead, and cannot hold the head up (neck flexor weakness). Distal hand grip and foot movements are preserved until late disease. This proximal-predominant, symmetric pattern is the key distinguishing feature from inclusion body myositis (asymmetric, distal-predominant) and from neurological conditions (myotomal or UMN distribution).

Progression and Complications

Dysphagia (~30%): Pharyngeal and upper esophageal striated muscles are affected by the same inflammatory process → difficulty swallowing, aspiration risk, and nasal regurgitation. Dysphagia is a marker of disease severity and a risk factor for aspiration pneumonia.
Interstitial lung disease (ILD): Anti-Jo-1 antibody (antisynthetase antibody) is present in approximately 20–30% of polymyositis patients and strongly predicts ILD. The combination of polymyositis + ILD + arthritis + mechanic's hands (cracked, fissured skin on fingertips) + Raynaud's phenomenon constitutes the antisynthetase syndrome.
Cardiac involvement: Myocarditis, conduction defects, and heart failure can occur — the same inflammatory process that attacks skeletal muscle can affect cardiac muscle, though less commonly.
Malignancy association: Polymyositis (and more strongly dermatomyositis) is associated with occult malignancy, particularly in patients diagnosed over age 40. The myositis may be a paraneoplastic phenomenon — autoimmune response triggered by tumor antigens cross-reacting with muscle antigens. Standard of care includes malignancy screening at diagnosis (CT chest/abdomen/pelvis, age-appropriate cancer screening).

Polymyositis vs. Dermatomyositis — Understanding the Overlap

Shared features: Both produce symmetrical proximal muscle weakness with elevated CK, respond to immunosuppressive treatment, and carry malignancy risk. EMG shows myopathic changes in both. Both are idiopathic inflammatory myopathies.
Key differences:

Feature	Polymyositis	Dermatomyositis
Skin findings	None	Heliotrope rash (violaceous discoloration of upper eyelids), Gottron's papules (erythematous plaques over MCP/PIP/DIP knuckles), shawl sign (photosensitive rash over shoulders/upper back), V-sign (anterior chest rash)
Immune mechanism	CD8+ T-cells attack muscle fibers directly (cell-mediated)	Complement-mediated attack on intramuscular vasculature (humoral)
Histology	Endomysial inflammation, muscle fiber invasion	Perimysial inflammation, perifascicular atrophy
Malignancy risk	Elevated	More elevated (dermatomyositis carries higher cancer association)
Antibodies	Anti-Jo-1 (antisynthetase), anti-SRP	Anti-Mi-2, anti-MDA5, anti-TIF1-gamma (cancer-associated)

Signs and Symptoms

Muscle Weakness Pattern

Symmetrical proximal weakness — the defining feature: difficulty rising from a seated position (hip flexor/quadriceps weakness), difficulty climbing stairs, difficulty reaching overhead or lifting objects (deltoid/shoulder girdle weakness), difficulty holding the head upright (neck flexor weakness)
Progression is typically subacute — developing over weeks to months, not days (acute onset suggests rhabdomyolysis or viral myositis) and not years (very slow progression suggests inclusion body myositis)
Distal strength (grip, foot dorsiflexion) is preserved until late disease
Bilateral involvement — affects both sides symmetrically

Associated Findings

Muscle pain and tenderness — variable; present in approximately 50% but not as prominent as the weakness; absence of pain does not rule out polymyositis
Fatigue — from chronic inflammation and muscle damage
Dysphagia — difficulty swallowing in ~30%; nasal regurgitation; choking; aspiration risk
Arthralgia — joint pain without deformity in some patients, especially in antisynthetase syndrome
No skin rash — this is what distinguishes polymyositis from dermatomyositis
Elevated CK — often 5–50 times normal; correlates with disease activity
Mechanic's hands (cracked, fissured fingertip skin) — suggests antisynthetase syndrome

Differentiating from Polymyalgia Rheumatica (PMR) — Critical Distinction

Feature	Polymyositis	Polymyalgia Rheumatica
Age	30–60 years	>50 years (rarely <50)
Primary complaint	Weakness (can't do things)	Pain and stiffness (hurts to do things)
True muscle weakness	Yes — measurable on MMT	No — strength normal when pain is controlled
CK	Markedly elevated (5–50x normal)	Normal
ESR	May be elevated	Markedly elevated (often >40)
Response to corticosteroids	Partial; requires high doses + immunosuppressants	Dramatic response to low-dose prednisone (10–20 mg) — "diagnostic response"
Distribution	Proximal weakness: can't rise from chair, can't reach overhead	Shoulder and hip girdle pain and stiffness; difficulty initiating movement
Association	Malignancy	Giant cell arteritis (temporal arteritis)

Assessment Profile

Subjective Presentation

Chief complaint: "I can't get up from the toilet without using my arms." "I can't lift my arms to wash my hair." Patients describe progressive difficulty with activities requiring proximal strength, typically developing over weeks to months. They distinguish weakness from pain — they are unable to do things, not just in pain when doing them.
Pain quality: Muscle aching that is diffuse and proximal — shoulders, upper arms, hips, thighs; variable in severity; some patients have minimal pain despite significant weakness; no joint swelling or warmth; pain is secondary to the weakness as the primary complaint
Onset: Subacute over weeks to months; insidious onset; patients often date the progression to specific functional milestones ("three months ago I could still climb the stairs; now I can't"); very rapid onset (days) suggests rhabdomyolysis or viral myositis; very slow onset (years) suggests inclusion body myositis
Aggravating factors: Activities requiring proximal strength (stairs, rising from chair, reaching overhead, lifting); sustained antigravity positions (holding arms overhead); activity tolerance decreases progressively over weeks
Easing factors: Rest (partial); corticosteroid treatment (reduces inflammation and improves strength over weeks); physical therapy maintains function during treatment
Red flags: Progressive dysphagia or voice changes → pharyngeal involvement with aspiration risk; refer urgently; new onset respiratory difficulty → interstitial lung disease or respiratory muscle weakness; refer urgently; dark urine (myoglobinuria) → severe muscle necrosis with risk of renal failure; emergency referral; unexplained weight loss in a patient >40 → screen for occult malignancy

Observation

Local inspection: Proximal muscle atrophy in established disease — visible wasting of deltoids, quadriceps, hip musculature; no visible skin rash (presence of rash → dermatomyositis); no joint swelling; may have mechanic's hands (cracked fingertips) if antisynthetase syndrome
Posture: Forward head posture from neck flexor weakness; rounded shoulders from deltoid/scapular stabilizer weakness; lordotic compensation from hip extensor/gluteal weakness; overall impression of reduced muscle bulk proximally
Gait: Waddling (Trendelenburg) gait from hip abductor weakness — pelvis drops on the swing-leg side due to insufficient contralateral hip stabilization; difficulty with stairs (holds railing, pulls with arms); may use a wide base for stability; gait may be relatively normal in early disease or mild cases

Palpation

Tone: Proximal muscles may feel soft and atrophic from chronic inflammation and fiber loss — reduced muscle bulk compared to expected for the patient's body habitus; in active disease, affected muscles may feel edematous (intramuscular inflammatory edema); there is no spasticity (this is a myopathy, not a neuropathy) and no significant hypertonicity (weakness, not guarding, is the primary finding); compensatory hypertonicity may develop in muscles that are overworking to compensate for proximal weakness (e.g., forearm muscles compensating for weak shoulder girdle, cervical extensors compensating for weak neck flexors)
Tenderness: Affected proximal muscles may be tender to palpation in approximately 50% of patients — tenderness indicates active inflammatory infiltration and ongoing muscle fiber necrosis; the presence of tenderness with proximal weakness and elevated CK strongly suggests active inflammatory myopathy; tenderness is diffuse within the muscle belly rather than localized to specific points or bands (distinguishes from MPS trigger points)
Temperature: Generally normal; no localized warmth over affected muscles (the inflammation is intramuscular, not superficial); if localized warmth is found over a joint, consider comorbid arthritis or overlap syndrome
Tissue quality: Affected muscles feel soft and reduced in bulk (atrophic) in established disease; in acute/active disease, muscles may feel edematous or boggy from inflammatory infiltrate; no fibrotic bands or ropy texture (distinguishes from chronic MPS); fascial mobility is typically preserved (the disease affects the muscle fibers, not the fascial envelope — unlike scleroderma); skin texture and integrity are normal (distinguishes from dermatomyositis)

Motion Assessment

AROM: Reduced in proximal movements — shoulder flexion/abduction limited by deltoid weakness, hip flexion limited by hip flexor/psoas weakness, neck flexion limited by neck flexor weakness; distal AROM (grip, finger movements, ankle dorsiflexion) is preserved until late disease; the limitation is from weakness, not from pain or structural restriction — patients cannot generate sufficient force to complete the movement against gravity
PROM / end-feel: Normal end-feel — PROM achieves full range because the joints and capsules are structurally normal; PROM significantly exceeds AROM (the critical finding — the patient lacks the muscle force to achieve full active range, but passive movement is unrestricted); this distinguishes polymyositis from capsulitis (where PROM is also restricted) and from OA (where end-feel is hard/bony)
Resisted testing: This is the most important assessment category. Symmetrical proximal weakness is measurable on manual muscle testing (MMT): grade 3–4/5 in shoulder abduction, hip flexion, and neck flexion; grade 4–5/5 in distal muscles (grip, wrist extension, ankle dorsiflexion); weakness is painless or only mildly painful on contraction; weakness is not myotomal or dermatomal — it is a pattern of proximal > distal, symmetric, and bilateral

Special Test Cluster

Polymyositis is diagnosed by clinical presentation (symmetrical proximal weakness), laboratory markers (elevated CK, specific autoantibodies), EMG (myopathic changes), and muscle biopsy (endomysial inflammation). The SOT cluster below focuses on quantifying the weakness pattern and differentiating from the most commonly confused conditions.

Test	Positive Finding	Purpose
Manual muscle testing — proximal pattern (CMTO)	Symmetrical weakness (grade 3–4/5) in shoulder abduction, hip flexion, hip abduction, and neck flexion; preserved distal strength	Confirm the proximal-predominant symmetric weakness pattern that defines inflammatory myopathy; quantify baseline for monitoring
Functional testing: chair rise without arms (CMTO)	Unable to rise from a standard-height chair without pushing off with the arms; or requires multiple attempts	Screen for clinically significant hip extensor/quadriceps weakness — the most functionally impactful deficit; highly sensitive for proximal weakness
Deep tendon reflexes (CMTO — rule out)	Normal (may be slightly reduced in severely atrophied muscles)	Rule out neurological cause of weakness: hyperreflexia → UMN (MS, stroke); hyporeflexia → LMN (radiculopathy, GBS); polymyositis produces myopathic weakness with normal reflexes
Skin inspection for dermatomyositis features (CMTO — rule out)	No heliotrope rash (upper eyelid), no Gottron's papules (knuckles), no shawl sign, no V-sign	Differentiate polymyositis (no skin findings) from dermatomyositis (characteristic skin rash); changes the malignancy risk assessment and antibody profile
Grip strength dynamometry (supplementary)	Preserved or mildly reduced grip strength compared to markedly reduced proximal strength	Confirm the proximal > distal weakness gradient; significant distal weakness suggests inclusion body myositis or a different diagnosis

If dysphagia reported: Add swallowing assessment and refer for formal dysphagia evaluation. Pharyngeal muscle involvement carries aspiration risk — the patient may need modified food textures and positioning precautions. Prone positioning during massage may increase aspiration risk if dysphagia is present.

Differential Assessment

Condition	Key Distinguishing Feature
Dermatomyositis	Same proximal weakness and elevated CK but with characteristic skin findings: heliotrope rash (violaceous upper eyelid discoloration), Gottron's papules (erythematous plaques over knuckles); higher malignancy association
Polymyalgia Rheumatica (PMR)	Age >50; pain and stiffness without true measurable weakness; CK is normal; ESR markedly elevated; dramatic response to low-dose corticosteroids; associated with giant cell arteritis, not malignancy
Inclusion Body Myositis (IBM)	Age >50 (typically); asymmetric weakness affecting distal muscles (finger flexors, quadriceps selectively); slow progression over years; poor response to immunosuppressive treatment; most commonly confused with PM in early evaluation
Statin Myopathy	Temporal association with statin initiation; proximal muscle pain > weakness; mildly elevated CK (usually <10x normal); resolves with statin discontinuation; may unmask or trigger true autoimmune myositis in susceptible individuals
Muscular Dystrophy	Genetic (not autoimmune); onset typically in childhood/adolescence; progressive weakness following specific patterns (Duchenne: proximal LE first; FSHD: face/shoulder first); CK elevated but no inflammatory infiltrate on biopsy; does not respond to immunosuppression

CMTO Exam Relevance

Know the defining triad: symmetrical proximal muscle weakness + elevated CK + endomysial inflammation on biopsy
Critical differential pair — polymyositis vs. PMR: PM = weakness + elevated CK; PMR = pain/stiffness + normal CK + dramatic steroid response + age >50
Know dermatomyositis skin findings (heliotrope rash, Gottron's papules) — their absence defines polymyositis by exclusion
Understand the malignancy association — particularly in patients diagnosed over age 40; this differentiates PM from PMR (which is associated with giant cell arteritis, not malignancy)
Know that anti-Jo-1 antibody predicts interstitial lung disease — the combination of myositis + ILD + mechanic's hands is antisynthetase syndrome
Classify as A4 (neurological/systemic) — though it is a myopathy, the autoimmune and systemic nature places it in the systemic conditions category
Active disease (elevated CK, muscle tenderness) is a contraindication to deep tissue work — inflamed muscles are actively being destroyed; deep pressure accelerates damage

Massage Therapy Considerations

Primary therapeutic target: secondary muscle tension and compensatory overload patterns that develop as weakened proximal muscles force other muscles to take over functional roles — cervical extensors compensating for neck flexor weakness, forearm muscles compensating for shoulder weakness, lumbar paraspinals compensating for hip weakness; MT does not treat the autoimmune myopathy itself
Active disease vs. stable/remission — the defining treatment decision:
Active disease (elevated CK, progressive weakness, muscle tenderness): deep tissue work is contraindicated — the muscles are actively being destroyed by inflammatory infiltration; deep pressure over inflamed muscle fibers accelerates necrosis and CK release; only very gentle relaxation massage is appropriate
Stable/remission (CK trending toward normal on treatment, weakness stabilized or improving, reduced tenderness): moderate-depth massage is appropriate for compensatory patterns; gentle work over previously affected muscles
Sequencing logic: Address compensatory overload first (the muscles working overtime because the proximal muscles are weak), then gently address the affected proximal muscles themselves with the primary goal of maintaining tissue quality and circulation — not deep release
Safety / contraindications:
Active disease: avoid deep pressure over affected muscles — inflamed, necrotic muscle fibers are vulnerable; CK level is the best indicator of disease activity (ask the patient about their most recent lab results)
Corticosteroid use (prednisone is first-line): skin fragility, easy bruising, subcutaneous tissue thinning, osteoporosis — use generous lubrication, conservative pressure, and tissue-guided assessment rather than relying on pain feedback
Immunosuppressant medications (methotrexate, azathioprine): the patient is immunocompromised — do not treat if the therapist has an active infection
Weakness: support all limbs during positioning; do not place the patient in positions requiring muscular effort to maintain — they cannot sustain the effort
Dysphagia: if present, avoid prone positioning — semi-reclined or side-lying preferred to reduce aspiration risk; monitor for coughing or choking during the session
Heat/cold guidance: Warm applications pre-treatment improve circulation to affected muscles and reduce compensatory muscle tension; appropriate in both active and stable disease; cold applications post-treatment if any area became reactive; no specific contraindications to heat or cold in polymyositis (unlike MS/Uhthoff's)

Treatment Plan Foundation

Clinical Goals

Reduce compensatory muscle tension in muscles overloaded by proximal weakness (cervical extensors, forearm muscles, lumbar paraspinals)
Maintain tissue quality and circulation in affected proximal muscles — prevent additional deterioration from disuse and deconditioning
Support overall relaxation and stress reduction — chronic autoimmune disease with malignancy association generates significant anxiety
Maintain joint ROM that could be lost from progressive weakness and immobility

Position

Side-lying or semi-reclined preferred — reduces the muscular effort required to maintain position; avoids prone positioning if dysphagia is present (aspiration risk)
Full bolster support for all limbs — the patient cannot sustain unsupported limb positions due to proximal weakness; arms supported on pillows, legs bolstered
If prone is used, ensure the patient can easily turn their head and that there is no pressure on the abdomen that could increase aspiration risk
Assist with all position changes — the patient may be unable to roll or reposition independently

Session Sequence

General effleurage to posterior trunk — assess tissue response; note areas of muscle atrophy (soft, reduced bulk) vs. compensatory tension (hypertonic areas); establish pressure tolerance particularly over the proximal muscles that may be actively inflamed
Cervical extensor and upper trapezius release — address the most common compensatory pattern (neck flexor weakness forces cervical extensors into constant overload); sustained compression and gentle longitudinal stripping
Scapular stabilizer and mid-back compensatory work — rhomboids, middle/lower trapezius, serratus anterior may be overloaded compensating for deltoid and rotator cuff weakness; gentle sustained techniques
Gentle effleurage and light kneading to proximal muscles (deltoids, upper arms, quadriceps, hip musculature) — [stable disease only; avoid if muscles are tender indicating active inflammation]; light-to-moderate pressure; purpose is to maintain circulation and tissue quality, not deep release; if the patient reports increasing tenderness, reduce pressure or move to a different area
Lumbar paraspinal and gluteal compensatory work — address overload from hip flexor and hip extensor weakness; gentle longitudinal stripping and sustained compression
Lower extremity circulatory effleurage — support circulation in limbs with reduced mobility; gentle rhythmic strokes
Closing general effleurage with progressive pressure reduction — promote parasympathetic state; allow rest; assist the patient off the table

Adjunct Modalities

Hydrotherapy: Pre-treatment warm application to the primary compensatory tension areas (upper back, cervical region) to improve tissue pliability; warm application to affected proximal muscles to improve circulation and comfort; no specific heat or cold contraindications in polymyositis
Remedial exercise (on-table): Gentle active-assisted ROM of affected proximal joints — therapist supports the limb while the patient moves through available range; purpose is to maintain joint mobility that could be lost from progressive weakness; do not perform resisted strengthening during the massage session — this is the role of the physical therapist's exercise program; gentle isometric contractions of compensatory muscles after release to maintain functional activation

Exam Station Notes

Demonstrate understanding of the proximal weakness pattern — test proximal muscles (shoulder abduction, hip flexion) and show that distal strength is preserved; state this finding as consistent with inflammatory myopathy
If the scenario specifies active disease, state that deep work over affected muscles is contraindicated due to active muscle fiber necrosis (elevated CK)
Demonstrate the polymyositis vs. PMR distinction — state: "This patient has measurable proximal weakness, which distinguishes this from polymyalgia rheumatica where strength is normal when pain is controlled"
Show awareness of dysphagia risk — if the patient has swallowing difficulty, state that prone positioning is avoided to reduce aspiration risk

Verbal Notes

Disease activity awareness: "Can you tell me how your last blood work looked — specifically your CK level? That helps me know how active the inflammation is right now and guides how deeply I can work on your muscles."
Positioning assistance: "I'll help you get into position and will support you when we need to change positions. Please don't try to lift yourself — just let me guide you."
Dysphagia precaution: [if dysphagia present] "Since swallowing is sometimes difficult for you, I'm going to keep you on your side/semi-reclined rather than face-down. If you need to cough or clear your throat at any time, let me know and I'll pause."
Post-treatment: "Your muscles may feel a bit more fatigued after the session. Plan to take it easy for the rest of the day — avoid heavy lifting or strenuous activity."

Self-Care

Maintain the physical therapy exercise program — gentle active ROM and graded strengthening prescribed by the physiotherapist are essential to prevent further deconditioning; do not exceed prescribed intensity (risk of exacerbating muscle damage during active disease)
Energy conservation and pacing — distribute demanding tasks throughout the day; use assistive devices when available (raised toilet seat, stair rails, shower chair); rest before reaching exhaustion
Report new symptoms promptly: difficulty swallowing, shortness of breath, dark-colored urine, or new skin rash (may indicate disease progression, complications, or transition to dermatomyositis)
Sun protection if on immunosuppressive medications — methotrexate and azathioprine increase photosensitivity risk

Key Takeaways

Polymyositis is an autoimmune inflammatory myopathy where CD8+ T-cells directly attack skeletal muscle fibers (endomysial inflammation), producing symmetrical proximal weakness with markedly elevated CK — the weakness is measurable and functional (can't rise from chair, can't reach overhead)
The critical differential from polymyalgia rheumatica: PM has true weakness with elevated CK; PMR has pain/stiffness with normal CK and normal strength when pain is controlled — PMR responds dramatically to low-dose steroids
Dermatomyositis shares the muscle disease but adds characteristic skin findings (heliotrope rash, Gottron's papules) — their absence defines polymyositis; dermatomyositis carries a higher malignancy association
Malignancy screening is standard of care at diagnosis and during follow-up — particularly in adults over 40; the myositis may be a paraneoplastic phenomenon
Active disease (elevated CK, muscle tenderness) contraindicates deep tissue work — inflamed muscles are actively being destroyed; only gentle relaxation techniques are appropriate
The primary MT target is compensatory muscle overload (cervical extensors for neck flexor weakness, lumbar paraspinals for hip weakness) — not the affected proximal muscles themselves
Dysphagia (~30% of patients) carries aspiration risk — avoid prone positioning; semi-reclined or side-lying preferred